The molecular docking indicated that BT2 exhibited a high docking score toward ABCB1 at the binding site, suggesting strong affinities with ABCB1, which explains the phenomenon that BT2 sensitized RCC cells to doxorubicin through competitive inhibition of the ABCB1 protein. This evidence concerns the gene ABCB1 and renal cell carcinoma.